Hydralazine

Introduction Overview

Generic Name

hydralazine

Brand Name

Apresoline

Dosage Form

oral tablet (10 mg; 25 mg; 50 mg; 100 mg)

Drug Class

vasodilators

Pharmacokinetics

Absorption:
Hydralazine is well absorbed following oral administration, exhibiting rapid and extensive absorption from the gastrointestinal tract. Peak plasma concentrations are typically reached within 30 to 60 minutes after ingestion of oral tablets. The oral bioavailability of hydralazine, however, is subject to significant first-pass metabolism, which results in considerable interindividual variability. In clinical settings, this variability can influence the onset and extent of antihypertensive effects. Studies have shown that food may modestly affect the absorption rate but not the extent, thus medications may be administered with or without regard to meals.

Distribution:
Once absorbed, hydralazine is distributed widely throughout bodily tissues and fluids. It has a moderate volume of distribution, reflecting penetration into various tissues including vascular smooth muscle. Hydralazine exhibits moderate plasma protein binding, facilitating its transport in circulation. Distribution into the central nervous system is limited but sufficient to produce some central side effects. Hydralazine does not accumulate significantly in tissues with repeated dosing, which correlates with its pharmacodynamic profile.

Metabolism:
Hydralazine undergoes extensive hepatic metabolism primarily through acetylation mediated by the enzyme N-acetyltransferase 2 (NAT2). Genetic polymorphisms of NAT2 result in 'slow' and 'fast' acetylator phenotypes, which significantly impact hydralazine's metabolism, plasma concentration, and therapeutic response. Slow acetylators demonstrate higher plasma levels and prolonged effects, but a greater risk of toxicity including lupus-like syndrome, whereas fast acetylators may require higher doses for efficacious treatment. In addition to acetylation, hydralazine is subject to hydroxylation and conjugation pathways. Metabolites are generally inactive.

Elimination:
Hydralazine and its metabolites are primarily excreted renally, with approximately 50-60% of a dose eliminated via urine, largely as inactive metabolites. The elimination half-life ranges from 3 to 7 hours but is shorter in fast acetylators and prolonged in slow acetylators. Because of variability in elimination, dosing intervals and titration require individualized consideration. Hepatic impairment may alter metabolism, necessitating cautious use. Renal dysfunction does not significantly affect hydralazine excretion but monitoring for adverse effects is advised. Overall, hydralazine’s pharmacokinetic profile necessitates dose adjustment based on individual metabolic capacity and clinical response.

Dosage Forms

Available Dosage Forms:
Hydralazine is available as oral tablets in several strengths to accommodate varied dosing needs. The approved strengths include 10 mg, 25 mg, 50 mg, and 100 mg tablets. These solid oral dosage forms allow for flexible dosing regimens to optimize blood pressure control.

Dosages for Adults and Adolescents:
For the management of hypertension, the initial dosage typically starts at 10 mg orally four times daily to maintain consistent plasma levels and minimize hypotensive episodes. Dosage titration may progress in increments of 25 mg every 3 to 7 days depending on therapeutic response and tolerance, with maintenance doses ranging from 40 mg to 200 mg daily divided into two to four doses. In some cases, up to 300 mg per day may be necessary but requires close monitoring. The maximum effective antihypertensive dose is usually reached at 200 mg daily. Hydralazine is usually administered alongside other antihypertensive agents such as beta-blockers and diuretics to mitigate reflex tachycardia and fluid retention.

Specific Patient Populations:
Hydralazine is not approved for pediatric patients under 18 years of age due to lack of established safety and efficacy data. In elderly patients, dosage adjustments may be necessary due to altered pharmacodynamics and increased sensitivity to vasodilators. Patients with hepatic impairment may require careful monitoring owing to possible reduced metabolic clearance. Pregnant women should be administered hydralazine only if clearly needed, as safety data are limited; it is often used cautiously in pregnancy-induced hypertension and preeclampsia under medical supervision. Breastfeeding mothers should consult healthcare providers before use, as hydralazine is excreted in breast milk but effects on infants are not well-defined.

Mechanism Of Action

Hydralazine is a direct-acting vasodilator that primarily acts on the smooth muscle cells of arterioles rather than veins. Its principal mechanism involves the relaxation of vascular smooth muscle by interference with intracellular calcium metabolism, leading to vasodilation and subsequent reduction of systemic vascular resistance. This selective arteriolar dilation lowers afterload, which decreases cardiac workload and lowers blood pressure.

At the molecular level, hydralazine affects multiple cellular pathways: it appears to inhibit inositol triphosphate-induced calcium release from the sarcoplasmic reticulum in vascular smooth muscle cells, thereby reducing intracellular calcium concentrations necessary for muscle contraction. Additionally, hydralazine may activate endothelial nitric oxide synthase, resulting in increased local nitric oxide production that acts as a potent vasodilator.

By reducing peripheral resistance, hydralazine induces a reflex sympathetic stimulation characterized by increased heart rate and myocardial contractility. Consequently, it is often co-administered with beta-adrenergic blockers to blunt these effects and prevent tachycardia. Its vasodilatory mechanism also improves tissue perfusion and oxygen delivery.

Clinically, the efficacy of hydralazine has been demonstrated in the treatment of essential hypertension and hypertensive emergencies, as well as in heart failure adjunct therapy to reduce afterload. Its mechanism differs from other vasodilators like minoxidil, which act on potassium channels, or nitrovasodilators such as nitroprusside, which donate nitric oxide directly. Research supports hydralazine’s unique biochemical interactions that contribute to its antihypertensive profile and distinct adverse effect profile, including lupus-like syndrome associated with its immunomodulatory potential in some patients.

Pharmacological Actions

Direct relaxation of vascular smooth muscle in arterioles leading to vasodilation
Reduction of systemic vascular resistance resulting in lowered blood pressure
Reflex sympathetic stimulation causing increased heart rate and myocardial contractility
Improvement of cardiac output by decreasing afterload in heart failure patients
Inhibition of intracellular calcium release within vascular smooth muscle cells
Activation of endothelial nitric oxide synthase enhancing local nitric oxide-mediated vasodilation
Modulation of vascular tone without significant effects on venous capacitance vessels
Potential immunomodulatory effects linked to lupus-like syndrome in susceptible patients
Synergistic effects when combined with beta-blockers to attenuate reflex tachycardia
Metabolic processing influenced by acetylation phenotype affecting pharmacodynamics
Limited central nervous system penetration reducing central side effects
Dose-dependent antihypertensive effects with significant interpatient variability
Minimal impact on renal blood flow allowing safe use in certain renal impairments
Distinct mechanism compared to ACE inhibitors, ARBs, and calcium channel blockers

Therapeutic Or Clinical Uses

Management of essential hypertension refractory to other antihypertensive agents
Treatment of moderate to severe hypertension requiring rapid blood pressure reduction
Adjunctive therapy in congestive heart failure to reduce afterload and improve cardiac output
Use in hypertensive emergencies and crises when parenteral formulations are available
Utility in pregnancy-induced hypertension when benefits outweigh potential risks
Combination therapy with beta-blockers and diuretics for better blood pressure control
Management of hypertensive patients with concomitant chronic kidney disease
Treatment of hypertension in patients intolerant to ACE inhibitors or ARBs
Occasional off-label use in systemic sclerosis-associated Raynaud’s phenomenon
Research application in studying vascular smooth muscle relaxation and vasoactive mechanisms
Use in patients with salt-sensitive hypertension as part of combination regimens
Adjunct agent to control resistant hypertension in complex cardiovascular patients
Potential use in certain cases of pheochromocytoma-induced hypertension pre-surgery
Occasional use in heart failure patients contraindicated or intolerant to ACE inhibitors

Side Or Adverse Effects

Chest pain or angina possibly related to reflex tachycardia and increased myocardial oxygen demand
Tachycardia and palpitations due to sympathetic nervous system reflex activation
Headache resulting from vasodilation and altered cerebral blood flow
Nausea, vomiting, and diarrhea as common gastrointestinal disturbances
Loss of appetite sometimes reported during prolonged therapy
Lupus-like syndrome presenting with arthralgia, fever, muscle aches, and skin rash particularly in slow acetylators
Peripheral neuropathy manifesting as numbness, tingling, or burning sensations in extremities
Hypotension with associated dizziness or lightheadedness, especially upon standing (orthostatic hypotension)
Rare but serious allergic reactions including angioedema and anaphylaxis
Fluid retention and edema as a consequence of vasodilation and compensatory renin-angiotensin activation
Positive antinuclear antibodies (ANA) in patients developing lupus-like symptoms
Palpitations and arrhythmias potentially exacerbated in patients with underlying cardiac disease
Fatigue and malaise impacting patient compliance during chronic use
Rare instances of hematologic abnormalities such as thrombocytopenia
Localized injection site reactions with parenteral formulations (if used)

Precautions

Use cautiously in patients with coronary artery disease due to risk of exacerbating angina
Monitor closely in patients with rheumatic heart disease affecting the mitral valve
Careful dosage titration in patients with systemic lupus erythematosus or predisposition to autoimmune disorders
Not recommended for use in children and adolescents under 18 years of age due to lack of safety data
Close monitoring in renal impairment though no significant dose adjustments required
Consider slow acetylator phenotype which heightens risk for adverse effects such as lupus-like syndrome
Avoid rapid discontinuation to prevent rebound hypertension
Use during pregnancy only if benefit justifies potential risk; monitor fetal status
Patients with history of stroke require cautious use due to blood pressure fluctuations
Monitor blood pressure frequently during initiation and dose adjustments
Assess for signs of drug-induced lupus including fever, joint swelling, and skin manifestations
Inform patients about orthostatic hypotension and advise gradual position changes
Evaluate for possible drug interactions that may potentiate hypotensive effects
Instruct patients to report any unusual neurological or cardiac symptoms immediately
Routine laboratory tests and clinical assessments recommended to evaluate efficacy and toxicity

Warnings

Contraindicated in patients with coronary artery disease due to potential to worsen myocardial ischemia
Do not use in individuals with rheumatic heart disease affecting the mitral valve to avoid exacerbation
Potential for life-threatening lupus-like syndrome with prolonged high-dose therapy
Risk of significant hypotension and reflex tachycardia necessitating careful dose titration
Not approved for pediatric use and safety in this population has not been established
Use with caution in pregnancy; insufficient data on teratogenicity or fetal risk
Compensatory fluid retention may worsen heart failure symptoms if unaddressed
May mask early symptoms of infection or autoimmune diseases due to immunomodulatory effects
Rare reports of severe allergic reactions including anaphylaxis require immediate discontinuation
Monitoring for hematologic abnormalities advised due to rare occurrences
Potential interactions with monoamine oxidase inhibitors leading to hypertensive crises
Increased risk of adverse cardiovascular events if used without adequate beta-blockade
May cause central nervous system effects, including headache and dizziness impairing activities
Patients should be warned about the possibility of drug tolerance with prolonged use
Abrupt cessation may result in rebound hypertension and associated complications

Contraindication

Known hypersensitivity or allergy to hydralazine or any component of the formulation
Patients with coronary artery disease due to risk of aggravating myocardial ischemia
Rheumatic heart disease impacting the mitral valve where hydralazine may worsen condition
Known history of drug-induced lupus or systemic lupus erythematosus due to risk of exacerbation
Pediatric patients under 18 years of age due to lack of established safety profile
Concurrent use with monoamine oxidase inhibitors without careful monitoring
Severe hypotension or shock states where vasodilation is contraindicated
Severe aortic or mitral valve stenosis as excessive vasodilation can compromise hemodynamics
Pregnancy unless clearly indicated and benefits outweigh risks
Patients with severe hepatic impairment unless under specialist supervision
Individuals with unstable angina or recent myocardial infarction
Unexplained muscle weakness or neuropathy where hydralazine side effects might worsen symptoms
Severe renal impairment without monitoring due to altered pharmacodynamics
Known sensitivity to other vasodilators which may indicate cross-reactivity
Patients with untreated pheochromocytoma without adequate alpha blockade

Drug Interactions

Concomitant use with monoamine oxidase inhibitors (MAOIs) such as isocarboxazid, phenelzine, or tranylcypromine may precipitate hypertensive crises
Concurrent administration with diazoxide can enhance hypotensive effects requiring dose adjustments
Combination with other antihypertensive agents including beta-blockers and diuretics can potentiate blood pressure lowering effects
Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate antihypertensive action by sodium and water retention
Use with other vasodilators may increase risk of excessive hypotension and reflex tachycardia
Co-administration with drugs metabolized via acetylation pathways may impact hydralazine clearance
Potential interaction with methylene blue causing serotonin syndrome when given with serotonergic agents
Use with sympathomimetic agents may counteract hydralazine’s antihypertensive effects
Risk of enhanced adverse cardiovascular effects when combined with other drugs causing reflex tachycardia
Concurrent use with central nervous system depressants may increase risk of dizziness and orthostatic hypotension
Interactions with medications affecting renal function may necessitate observation for fluid retention
Herbal supplements with hypotensive properties like garlic or hawthorn may additive effects
Combination with lithium may alter lithium plasma concentrations and toxicity
Co-administration with hydralazine and MAO inhibitors requires close monitoring for hypertensive emergencies
Potential for interaction with warfarin affecting anticoagulation status, close INR monitoring advised

Preparations Of The Drug

Hydralazine oral tablets available in 10 mg strength for initiation and titration
Oral tablet formulations also include 25 mg, 50 mg, and 100 mg strengths to customize dosing
Parenteral formulations (injectable hydralazine) used in hypertensive emergencies, available separately
Tablets are formulated for standard oral administration, consistent release, and stability
Available commercially under the brand name Apresoline and generic equivalents
Oral tablets should be stored at room temperature, protected from excess moisture and heat
Packaging ranges from blister packs for outpatient use to bulk bottles for hospital settings
Manufactured under Good Manufacturing Practices (GMP) with rigorous quality control
Additional strengths or compounded formulations may be prepared in specialized settings for pediatric or unusual dosing needs
Parenteral hydralazine supplied in sterile vial form for intravenous or intramuscular administration
Hydralazine tablets are not scored; dosage adjustments require use of varying tablet strengths
Solid dosage forms are preferred for long-term management due to ease of administration
Patient information leaflets accompany preparations with detailed dosing and safety instructions
Hydralazine injection requires dilution and slow intravenous administration under close monitoring
Generic and branded preparations undergo equivalence testing to ensure therapeutic consistency